Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirdametinib in Pediatric Low-Grade Glioma
NCT04923126Phase 2Recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Jun 2021
- Primary completion
- Jun 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of mirdametinib in glioma (5 arms), sponsored by St. Jude Children's Research Hospital. Primary endpoints: Maximum Tolerated Dose / Recommended Phase 2 Dose at 1 month, Safety and Tolerability at 25 months and 4 more. Started Jun 2021; status: recruiting.
02
Drugs
mirdametinib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT04923126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04923126.